Rituximab
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Rituximab. This is a genetically engineered monoclonal antibody. Fully referenced neurology checklist.
Characteristics
- This is a genetically engineered monoclonal antibody
- It binds to CD20 antigen on pre-B and mature B lymphocytes
- B cell repletion begins within 6 months of treatment
- Repletion is complete in 9-12 months
Neuroinflammatory indications
Locked: subscribe to see this section.
Neuromuscular junction and muscle indications
Locked: subscribe to see this section.
Neuropathy indications
Locked: subscribe to see this section.
Other indications
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Pre-infusion precautions
Locked: subscribe to see this section.
Side effects: cytokine release syndrome
Locked: subscribe to see this section.
Side effects: others
Locked: subscribe to see this section.
References
- Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175:408-418.
- Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010: 3 93-105.
- Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013; 8:e66308.
- Torkildsen Ø, Brustad HK, Høgestøl EA, et al. Rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. N Engl J Med 2026; 395:44-53.
- Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013; 70:1110-1117.
- And 6 more. Subscribe to see the full list
